Most practitioners order a fasting glucose and call it done. If the number is normal, blood sugar comes off the differential. But fasting glucose is a single snapshot of a system that operates in constant flux — and the patients sitting in your office with unresolved fatigue, cognitive slowing, and diffuse pain may be showing you the consequences of that flux every single visit.
Dr. Datis Kharrazian's clinical training at the Kharrazian Institute addresses this gap directly. Blood sugar dysregulation — dysglycemia — is one of the most commonly missed drivers of chronic fatigue, and standard lab interpretation often fails to catch it until significant metabolic damage has already occurred. The research in functional medicine and metabolic neurology makes the mechanism clear. The clinical skill is learning to see it before the labs confirm it.
Why Standard Screening Misses Blood Sugar Dysregulation Fatigue
Fasting glucose and even HbA1c reflect average and resting states. They tell you almost nothing about what happens when a patient eats, what their glucose does two hours postprandial, how far it swings, or how their brain responds to that swing.
Dysglycemia is not a diagnosis — it is a spectrum. On one end: reactive hypoglycemia, where glucose drops sharply after a meal and produces fatigue, irritability, and cognitive fog within 90 minutes of eating. On the other: insulin resistance with chronic hyperglycemia, where sustained high glucose drives oxidative stress, mitochondrial dysfunction, and neuroinflammation. Both ends of that spectrum produce fatigue. Both are routinely missed on standard panels.
The clinical presentation that should raise your index of suspicion: fatigue that worsens after eating (not before), energy that is disproportionate to sleep quality, concentration that deteriorates predictably after meals, and mood changes tied to food timing rather than circumstance. These are not vague complaints. They are a metabolic pattern.
The Brain Pays First When Glucose Becomes Unstable
The brain consumes roughly 20 percent of the body's glucose while representing only two percent of body weight. It has no glycogen reserve of consequence. When blood sugar fluctuates — whether through reactive drops or sustained elevation — the brain is the first organ to show functional consequences.
Research in metabolic neurology demonstrates that chronic glucose instability reduces cerebral glucose uptake, drives neuroinflammation through advanced glycation end products, and impairs mitochondrial ATP production in neurons. The clinical expression of those mechanisms is cognitive slowing, word retrieval difficulty, attention fragmentation, and persistent low-grade fatigue that no amount of sleep resolves.
Dr. Kharrazian's coursework teaches practitioners to recognize a critical distinction: brain fatigue and body fatigue can have different origins, and glucose instability tends to affect both simultaneously. When a patient reports that they are physically tired and mentally foggy together — and that pattern clusters around meals — dysglycemia deserves serious consideration before attributing either symptom to depression, anemia, or poor sleep hygiene.
The longer-term implication is not trivial. Research in neurodegenerative disease consistently identifies insulin resistance as a significant risk factor for cognitive decline. Type 3 diabetes is the informal term some researchers use for the insulin-resistant brain. When early cognitive complaints are dismissed in a patient with unidentified dysglycemia, a treatable metabolic driver gets left in place while the neurodegenerative risk accumulates.
Chronic Pain and Dysglycemia: The Connection Practitioners Overlook
Chronic pain patients are rarely evaluated for blood sugar dysregulation, yet the mechanistic connection is well-established. Elevated blood glucose sustains systemic inflammation through multiple pathways: activation of the NF-κB inflammatory cascade, increased production of pro-inflammatory cytokines, oxidative stress from mitochondrial glucose overload, and direct damage to peripheral nerve endings through advanced glycation.
Peripheral neuropathy is the recognized endpoint of chronic hyperglycemia. What gets less clinical attention is the earlier phase — diffuse musculoskeletal pain, joint aching, and heightened pain sensitivity in patients who are not yet diagnosably diabetic but whose glucose regulation is already compromised. The inflammatory environment created by dysglycemia lowers pain thresholds systemically. That patient presenting with fibromyalgia-like symptoms and fatigue may not have a central sensitization disorder as the primary driver. They may have uncontrolled metabolic inflammation.
Dr. Kharrazian's clinical teaching emphasizes that when a chronic pain patient's symptoms worsen after high-carbohydrate meals or improve with dietary modifications that stabilize glucose, the assessment needs to shift toward metabolic evaluation, not just pain management.
Clinical Assessment That Actually Captures Glucose Variability
A meaningful dysglycemia workup goes beyond a fasting glucose. The full picture requires evaluating multiple timepoints and metabolic markers together.
Fasting glucose alone misses postprandial dysregulation entirely. HbA1c reflects a 90-day average and will appear normal in a patient with significant glucose swings that average out to an acceptable mean. Fasting insulin is essential — a patient can have a normal fasting glucose and a fasting insulin of 15 or 20, indicating substantial insulin resistance that the glucose alone would never reveal. Postprandial glucose at one and two hours captures reactive patterns. A two-hour postprandial above 120 mg/dL in a symptomatic patient warrants clinical attention even when it falls within conventional reference ranges.
The functional medicine reference ranges taught in Dr. Kharrazian's coursework reflect this: fasting glucose ideally between 85 and 99 mg/dL, fasting insulin below 5 µIU/mL, and HbA1c below 5.5 percent. These tighter targets are not arbitrary — they reflect the glucose levels at which brain function, mitochondrial performance, and inflammatory tone are best supported by the available research.
Continuous glucose monitoring has changed the clinical picture significantly. For patients who can tolerate wearing a monitor for two to four weeks, the data reveals exactly what fasting labs cannot: the amplitude of postprandial spikes, the frequency and depth of reactive drops, the nocturnal glucose patterns, and how specific foods, stress, and sleep affect glucose in real time. That data is actionable in a way that quarterly labs cannot match.
The intake history matters as much as the lab panel. Direct questions about energy timing relative to meals, cognitive performance after eating, food cravings (particularly carbohydrate cravings in the afternoon), sleep quality, and symptom variability across the day will often point directly to dysglycemia before a single lab is ordered. Patients are giving you the diagnosis — the clinical skill is knowing which questions surface it.
What Functional Medicine Dysglycemia Management Looks Like in Practice
The intervention hierarchy in functional medicine dysglycemia management starts with diet and moves through targeted support. Dietary intervention — specifically reducing refined carbohydrate load, increasing protein and fat at each meal to slow glucose absorption, and establishing consistent meal timing — is foundational and often produces rapid symptomatic improvement. Patients with reactive hypoglycemia frequently report that small, frequent protein-containing meals resolve fatigue within days. That speed of response is itself diagnostically informative.
Nutritional support for insulin sensitivity is backed by substantial research. Berberine, alpha-lipoic acid, chromium, magnesium, and inositol have all demonstrated effects on insulin signaling in peer-reviewed literature. These are not replacements for dietary change. They are adjuncts to it when the clinical picture warrants additional support.
For patients with documented insulin resistance and significant neurological symptoms — cognitive slowing, peripheral neuropathy, chronic fatigue unresponsive to other interventions — the clinical strategy needs to be comprehensive: dietary intervention, targeted nutritional support, exercise (which independently improves insulin receptor sensitivity), and stress management (because cortisol directly raises blood glucose and worsens insulin resistance).
The practitioner's goal is not a lab number. It is a patient who reports consistent energy across the day, no postprandial fatigue, clear cognitive function after meals, and resolution of the diffuse pain that was previously attributed to something else entirely.
Key Takeaways
- Fasting glucose and HbA1c alone are insufficient to rule out clinically significant blood sugar dysregulation in chronic fatigue patients
- The brain is disproportionately affected by glucose instability — cognitive slowing and mental fatigue that cluster around meals are a metabolic signal, not a psychiatric one.
- Fasting insulin and postprandial glucose testing are essential components of a functional dysglycemia workup; functional reference ranges differ meaningfully from conventional cutoffs.
- Chronic diffuse pain in the absence of a clear musculoskeletal diagnosis warrants metabolic evaluation, including glucose and insulin markers.
- Dietary intervention produces measurable symptomatic improvement quickly in reactive hypoglycemia — speed of response is itself a diagnostic indicator.
Frequently Asked Questions
Dysglycemia refers to abnormal blood glucose regulation that includes insulin resistance, reactive hypoglycemia, and postprandial glucose spikes — conditions that occur well before a diabetes diagnosis. Many patients with significant dysglycemia have fasting glucose and HbA1c values that fall within conventional normal ranges.
Yes. Reactive hypoglycemia and insulin resistance both produce fatigue through different mechanisms — glucose drops trigger the adrenal stress response, while insulin resistance reduces cellular energy production. Both present as fatigue, and neither requires a diabetes diagnosis to be clinically significant.
A comprehensive panel includes fasting glucose, fasting insulin, HbA1c, and one- and two-hour postprandial glucose. Fasting insulin is particularly informative — it can reveal insulin resistance when fasting glucose remains normal. Functional reference ranges for these markers are tighter than conventional cutoffs.
The brain depends on stable glucose availability and has minimal glycogen storage. Glucose swings reduce cerebral glucose uptake, increase neuroinflammation, and impair mitochondrial ATP production in neurons. Chronic instability is associated with accelerated cognitive decline and increased neurodegenerative risk in the research literature.
Continuous glucose monitoring provides data on postprandial spikes, reactive drops, nocturnal patterns, and food-specific responses that no quarterly lab panel can capture. For patients with unresolved fatigue, cognitive complaints, or chronic pain, two to four weeks of monitoring can identify glucose patterns that directly guide clinical intervention.
About the Author
Dr. Datis Kharrazian, PhD, DHSc, DC, MS, MMSc, FACN is a Harvard Medical School research fellow and researcher at Massachusetts General Hospital in the Department of Neurology, specializing in autoimmunity and neuroimmunology. He is an Associate Clinical Professor at Loma Linda University School of Medicine, and the author of Why Do I Still Have Thyroid Symptoms When My Lab Tests Are Normal and Why Isn't My Brain Working. Dr. Kharrazian is a Fellow of the American College of Nutrition, a Diplomate of the Board of Nutrition Specialists, a member of the American Association of Immunologists, and a Fellow of the Royal Society of Medicine (UK). The Kharrazian Institute serves more than 5,000 physicians and healthcare providers worldwide.
Clinical training in functional dysglycemia assessment and management is available through the Kharrazian Institute. Courses cover comprehensive metabolic evaluation, functional lab interpretation, and evidence-based protocols for blood sugar dysregulation in complex chronic patients. Visit kharrazianinstitute.com to review available coursework.
